Therapies to either decrease angiotensin II or increase angiotensin-(1–7) levels and actions systemically are effective at improving integrated cardiometabolic function in obesity, although further studies are needed to better understand precise mechanisms involved in these effects and how to translate these findings clinically, particularly for angiotensin-(1–7) pathways. Here, AGT is linked to obesity disorder.